|  | 

General

AllaChem Announces a Successful Completion of Phase 1 Clinical Study With AV4025, a Potent Small Molecule HCV NS5A Inhibitor for the Treatment of Chronic Hepatitis C Infection

HALLANDALE BEACH, FL–(Marketwired – Nov 13, 2013) – AllaChem, LLC announced today a successful completion of phase 1 clinical study with AV4025, a proprietary orally-bioavailable small molecule that blocks HCV genome replication by targeting viral non-structural protein NS5A. A double-blind, placebo-controlled, single ascending oral dose study with AV4025 showed safety and tolerability in healthy volunteers. Each dose cohort (10 subjects per cohort) received a single dose of 10, 20, or 40 mg of AV4025, or placebo (drug: placebo ratio 4:1). The drug was safe, well-tolerated; and no significant adverse events (SAE) were reported. The pharmacokinetic analyses demonstrated high and dose-dependent drug exposure in plasma, as well as long half-elimination time, supportive of once daily dosing.

Prof. Alexander Ivachtchenko, AllaChem’s CEO, stated: “We are very pleased with the safety and pharmacokinetic profiles of AV4025 in this first-in-man study. Further clinical study with AV4025 is scheduled to begin in the HCV patients in Q1 of 2014.”

Contact Information

Media CONTACT:
Alena Ivachtchenko, MBA
Director Business Development
Phone: 1-858-35-6627
E-mail: alena.ivachtchenko@allachem.com; av@allachem.com
www.allachem.com

allachem-announces-a-successful-completion-of-phase-1-clinical-study-with-av4025-a-potent-small-molecule-hcv-ns5a-inhibitor-for-the-treatment-of-chronic-hepatitis-c-infection

ABOUT THE AUTHOR

POST YOUR COMMENTS

About Us

Yes, it is true that the Business Observer does what its name reveals, means covering the news from all the industries, which are putting their efforts into accelerating the economy of Pakistan.

Monthly Archives

Categories

ad news